Autres langues Lundbeck Nasdaq Copenhagen

Actions

LUN

DK0061804697

Produits pharmaceutiques

Marché Fermé - Nasdaq Copenhagen 17:20:00 18/08/2026			Varia. 5j.	Varia. 1 janv.
36,85 ^DKK	+1,24%		+3,95%	+1,80%

17/08	Lundbeck devrait publier un Ebitda ajusté de 1 945 millions de couronnes danoises - consensus	FW
13/08	Mikael Dolsten rejoint le conseil d'administration de Quantumcell	FW

Autres langues

11/08	Moberg Pharma Appoints Business, Medical Chiefs
23/07	Lundbeck Receives FDA Fast Track Designation for Lu AH69593, Investigational Orexin 2 Receptor Agonist for Narcolepsy
23/07	Lundbeck Secures US FDA Fast Track Designation for Narcolepsy Drug
23/07	Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
20/07	H. Lundbeck A/S Completes Randomization In DEEp OCEAN Phase III Clinical Trial Evaluating Bexicaserin For Treatment Of Seizures Associated With Developmental And Epileptic Encephalopathies
20/07	Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
14/07	Where would AI lead Pharma in the long run?
24/06	H. Lundbeck A/S Announces Executive Changes
24/06	Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
24/06	Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
14/06	Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
14/06	H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease
10/06	Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
04/06	H. Lundbeck Presents Positive Phase IIb Data For Bocunebart In Migraine Prevention
04/06	Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
03/06	Lundbeck Enters Partnership with Cradle for Brain Disorder Therapies
03/06	Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
26/05	Lundbeck Obtains Marketing Permit for Migraine Drug Vyepti in South Korea
26/05	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
26/05	H. Lundbeck A/S Receives Marketing Authorization for Vyepti (Eptinezumab) in South Korea for Preventive Treatment of Migraine
19/05	H Lundbeck A/S : Transcript (Transcript)
18/05	Lundbeck's Asedebart Secures Orphan Drug Designation in Japan
18/05	Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
13/05	H Lundbeck : Strong Q1, but long-term growth uncertainty hovers over valuation
13/05	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck Q1 2026 FINAL)